Nuvation Bio Inc. (NUVB)

Market Cap	743.81M
Revenue (ttm)	2.16M
Net Income (ttm)	-532.28M
Shares Out	336.57M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,743,866
Open	2.300
Previous Close	2.270
Day's Range	2.200 - 2.330
52-Week Range	1.670 - 4.160
Beta	1.45
Analysts	Strong Buy
Price Target	7.67 (+247.06%)
Earnings Date	Mar 3, 2025

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC)...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 51
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Analyst Forecast

According to 6 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price forecast is $7.67, which is an increase of 247.06% from the latest price.

Price Target

$7.67

(247.06% upside)

Analyst Consensus: Strong Buy